New psoriasis drug SHR-1139 enters first human trials
NCT ID NCT07051538
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new drug called SHR-1139 in healthy volunteers and people with moderate-to-severe plaque psoriasis. The main goal is to check safety and how the body handles the drug. A total of 64 participants will receive either the drug or a placebo, with doses given as injections under the skin or into a vein.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SHR-1139 injection
- What this could lead to
- If successful, this could lead to a new treatment option for moderate-to-severe plaque psoriasis, potentially offering better disease control.
- What could go wrong
- This is an early Phase 1 trial with only 64 participants, focused on safety and dosing. It is too small and early to know if the drug will effectively treat psoriasis or have serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATE TO SEVERE PLAQUE PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Huashan Hospital, Fudan University
Shanghai, Shanghai Municipality, 200031, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Once-Weekly pill clear stubborn psoriasis?
- New oral pill aims to clear psoriasis in major trial
- New biologic drug netakimab tested in kids with psoriasis
- New study monitors how fast psoriasis drugs work in daily life
- New psoriasis drug shows promise for teens in early trial
- Could a diabetes drug boost psoriasis treatment in overweight patients?